

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 15824

Title: MET inhibitors for the treatment of advanced hepatocellular carcinoma: A review

Reviewer's code: 00503516

Reviewer's country: Italy

Science editor: Ya-Juan Ma

Date sent for review: 2014-12-11 16:39

Date reviewed: 2014-12-22 22:30

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Xingshun Qi et described the studies about the use of MET inhibitors as potential novel treatments for the advanced stages of HCC reporting ongoing and completed clinical trials. The review is clearly written and gives a reasonable overview of the topic. I just suggest to slightly expanding, in the "Introduction" the biochemical pathway involved in MET inhibition. Finally, few words about the different chemical structures of the anti-MET molecules described may be useful.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 15824

Title: MET inhibitors for the treatment of advanced hepatocellular carcinoma: A review

Reviewer's code: 00503849

Reviewer's country: China

Science editor: Ya-Juan Ma

Date sent for review: 2014-12-11 16:39

Date reviewed: 2014-12-21 14:02

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This review manuscript extensively described and summarized the results of recent clinical trials related to mesenchymal epithelial transition tyrosine kinase inhibitors in the treatment of advanced hepatocellular carcinoma. The potential utility of these kinase inhibitors in hepatocellular carcinoma patients was also discussed. The manuscript can provide useful information to the readers. I recommend publishing this manuscript. Minor comment: The abbreviation of MET in section of abstract should be spelled in full in its first appearance.